Pfizer (PFE) Completes Acquisition of ReViral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Pfizer Completes Acquisition of ReViral
June 9, 2022 10:00 AM EDTAcquisition expands Pfizers anti-infective pipeline and reinforces commitment to developing both medicines and vaccines to help combat respiratory syncytial virus (RSV)
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and... More
